Cirio advises Intervacc in connection with Exclusive Distribution Agreement

Cirio advises Intervacc in connection with Exclusive Distribution Agreement

Intervacc AB (publ) has entered into an exclusive distribution agreement with Dechra Pharmaceuticals PLC to commercialize Intervacc’s leading vaccine candidate Strangvac® in Europe, excluding the Nordic and Baltic countries. Strangvac® is in late-stage regulatory review with the European Medicines Agency and is an innovative vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. The distribution agreement is based on a transfer price plus additional future payments linked to pre-defined sales milestones.

Cirio’s team consisted of Senior counsel Anders Burén, partner Ulrica Salomon and associate Anna Hovstadius.